Coordinated Care to Optimize Treatment in Patients With Diabetes and Cardiovascular Disease, Panitumumab vs Bevacizumab Added to Chemotherapy for Metastatic Colorectal Cancer, USPSTF Recommendation on Screening for Skin Cancer, and more
JAMA Editors' Summary
00:00
A National Hepatitis C Elimination Program in the United States: A Historic Opportunity
More than half of the top-selling drugs in Medicare did not receive a moderate or high added therapeutic benefit rating. These drugs accounted for over 19 billion in net spending, or 11 percent, of Medicare's net prescription drug spending in 2020. The Biden-Harris administration has proposed a five-year program to eliminate hepatitis C in the United States.
Transcript
Play full episode
